Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Clinical Outcome
17 results:

  • 1. Association of xpd Lys751Gln gene polymorphism with susceptibility and clinical outcome of colorectal cancer in Pakistani population: a case-control pharmacogenetic study.
    Gul S; Khan A; Raza A; Khan I; Ehtisham S
    Genes Genomics; 2020 Dec; 42(12):1389-1398. PubMed ID: 33025549
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Nucleotide excision repair pathway gene polymorphisms are associated with risk and prognosis of colorectal cancer.
    Li YK; Xu Q; Sun LP; Gong YH; Jing JJ; Xing CZ; Yuan Y
    World J Gastroenterol; 2020 Jan; 26(3):307-323. PubMed ID: 31988591
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial.
    Boige V; Mollevi C; Gourgou S; Azria D; Seitz JF; Vincent M; Bigot L; Juzyna B; Miran I; Gerard JP; Laurent-Puig P
    Int J Cancer; 2019 Dec; 145(11):3163-3172. PubMed ID: 31107542
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Predictive Value of ERCC1, ercc2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
    Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
    Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. AGXT and ercc2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
    Kjersem JB; Thomsen M; Guren T; Hamfjord J; Carlsson G; Gustavsson B; Ikdahl T; Indrebø G; Pfeiffer P; Lingjærde O; Tveit KM; Wettergren Y; Kure EH
    Pharmacogenomics J; 2016 Jun; 16(3):272-9. PubMed ID: 26261061
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Predictive value of ERCC1, ercc2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. GSTP1, ERCC1 and ercc2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.
    Li HY; Ge X; Huang GM; Li KY; Zhao JQ; Yu XM; Bi WS; Wang YL
    Asian Pac J Cancer Prev; 2012; 13(7):3465-9. PubMed ID: 22994779
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish ttd Group Study.
    Sastre J; Grávalos C; Rivera F; Massuti B; Valladares-Ayerbes M; Marcuello E; Manzano JL; Benavides M; Hidalgo M; Díaz-Rubio E; Aranda E
    Oncologist; 2012; 17(3):339-45. PubMed ID: 22363067
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
    Huang MY; Huang ML; Chen MJ; Lu CY; Chen CF; Tsai PC; Chuang SC; Hou MF; Lin SR; Wang JY
    Pharmacogenet Genomics; 2011 Jan; 21(1):18-25. PubMed ID: 21057378
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
    Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
    Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P
    J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The value of xpd and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.
    Artac M; Bozcuk H; Pehlivan S; Akcan S; Pehlivan M; Sever T; Ozdogan M; Savas B
    J Cancer Res Clin Oncol; 2010 Jun; 136(6):803-9. PubMed ID: 19908066
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.
    Paré L; Marcuello E; Altés A; del Río E; Sedano L; Salazar J; Cortés A; Barnadas A; Baiget M
    Br J Cancer; 2008 Oct; 99(7):1050-5. PubMed ID: 18797464
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, xpd, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
    Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
    Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
    Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei DD; Groshen S; Lenz HJ
    Cancer Res; 2001 Dec; 61(24):8654-8. PubMed ID: 11751380
    [TBL] [Abstract] [Full Text] [Related]  

    of 1.